105 results about "Disease process" patented technology

A method of assessing risk for an individual to experience a specific outcome within a disease entity within a specified time frame is provided. Peer-reviewed scientific publications are analyzed to identify pertinent risk factors (212) for developing disease processes and their possible complications. Information that characterizes an individual (218) in relation to the identified risk factors is then received, preferably responsive to question (224) regarding any demographic values of an individual under test and questions regarding medical chracterisitics of the individual under test. An estimate of risk of the individual acquiring the outcome within a specified time frame is performed based on the identified plurality of risk factors (212). Assessment of medical risk and condition may include analyzing peer-reviewed scientific publications to identify populations affected by a medical outcome and for each population respective risk factors that affect risk of acquiring the medical outcome within a specified time-frame, associating an individual with one of the identified population, identifying information that characterizes the individual (218) in relation to the respective risk factors other associated population, and estimating risk of the individual having the medical outcome within the specified the time frame responsive to the identified information. Promotion of business on a site of a computer network is provided by supplying an on-line questionnaire (224) regarding characteristics of individual (218) under test, receiving information regarding characteristics of the individual under test, and responsive to the received information, providing an assessment of the individual under test having a medical outcome within a specified time frame.

A system and method for disease management that effectively eliminates unnecessary layers and / or intermediaries within the healthcare management system by enabling a disease management entity to operate as an extension of a physician's office, and thus, work closely with the patients and the patient's physicians to effectively empower patients towards self-care and a higher level of awareness and understanding of their disease process and treatment. The present system and method utilizes a team of highly trained healthcare professionals and technicians working together with patients and physicians, wherein remote vital sign monitoring equipment, software systems, and standing orders and treatment protocols, are utilized to effectively manage patients with chronic conditions. Additionally, as the disease management entity operates as an extension of a physician's office, the disease management entity is able to coordinate with a payor through the physician's office, and thus provide the payor with positive financial outcomes.

The present invention uses peripheral blood monocyte-lymphocyte for the early diagnosis of pancreatic cancer, as well as other conditions of the pancreas and other organs. The peripheral blood lymphocytes recognize the new neoplasm in the pancreas, as well as disease processes in other organ systems. The evaluation of this specific recognition of the disease process by the peripheral blood monocyte-lymphocyte through gene microarray expression patterns constitute a successful method for the early detection of pancreatic cancer and other organ disease processes. This document describes the process used in this method of early diagnosis.

An integral laser imaging and treatment apparatus, and associated systems and methods that allow a physician (e.g., a surgeon) to perform laser surgical procedures on an eye structure or a body surface with an integral laser imaging and treatment apparatus disposed at a first (i.e. local) location from a control system disposed at a second (i.e. remote) location, e.g., a physician's office. In some embodiments, communication between the integral laser imaging and treatment apparatus and control system is achieved via the Internet®. Also, in some embodiments, the laser imaging and treatment apparatus includes a dynamic imaging system that verifies the identity of a patient, and is capable of being used for other important applications, such as tracking and analyzing trends in a disease process. Further, in some embodiments, the laser imaging and treatment apparatus determines the geographical location of the local laser generation unit of the system using GPS.

The present invention describes polynucleotides that have been discovered to correlate to the relative intrinsic sensitivity or resistance of cells, e.g., lung cell lines, to treatment with compounds that interact with and modulate, e.g., inhibit, protein tyrosine kinases, such as, for example, members of the Src family of tyrosine kinases, e.g., Src, Fgr, Fyn, Yes, Blk, Hck, Lck and Lyn, as well as other protein tyrosine kinases, including, Bcr-abl, Jak, PDGFR, c-kit and Ephr. These polynucleotides have been shown, through a weighted voting cross validation program, to have utility in predicting the resistance and sensitivity of lung cell lines to the compounds. The expression level of some polynucleotides is regulated by treatment with a particular protein tyrosine kinase inhibitor compound, thus indicating that these polynucleotides are involved in the protein tyrosine kinase signal transduction pathway, e.g., Src tyrosine kinase. Such polynucleotides, whose expression levels correlate highly with drug sensitivity or resistance and which are modulated by treatment with the compounds, comprise polynucleotide predictor or marker sets useful in methods of predicting drug response, and as prognostic or diagnostic indicators in disease management, particularly in those disease areas, e.g., lung cancer, in which signaling through the protein tyrosine kinase pathway, such as the Src tyrosine kinase pathway, is involved with the disease process.

The disclosed innovation is a method for acquiring spatial frequency spectra from specific locations in a 3D sample using modifications of the current MRI techniques for localized NMR spectroscopy. The innovation in its simplest abstraction is to add the use of a read out gradient to the current NMR spectroscopy pulse sequences and record the resultant echo. These techniques generate spectra from a selected region or generate an image of the results over a region of the sample. These methods can be applied to analyzing the structure of trabecular bone as well as for analyzing or diagnosing disease in cases where there is a difference in the spatial frequency power spectrum due to physiologic or disease processes. Various embodiments are disclosed.

This invention relates to the use of ADNF polypeptides in the treatment of neurotoxicity induced by chemical agents or by disease processes. The ADNF polypeptides include ADNF I and ADNF III (also referred to as ADNP) polypeptides, analogs, subsequences such as NAP and SAL, and D-amino acid versions (either wholly D-amino acid peptides or mixed D- and L-amino acid peptides), and combinations thereof which contain their respective active core sites.

Certain embodiments of the present invention provide a system and method for image registration and display of relevant information. The method includes identifying one or more anatomical parts in an acquired image, mapping the acquired image to a reference image based on the one or more anatomical parts, storing anatomy information in relation to the acquired image, and displaying the acquired image based on the anatomy information. The method may also include controlling the displaying of the acquired image based on a voice command related to the anatomy information. Anatomy information may be displayed with the acquired image. Anatomy information may include clinical information, reference information, disease process information, a related image, and / or drug interaction information, for example. The acquired image may be displayed according to a display setting, such as a window level setting and / or other display setting, based on the anatomy information.

Predicting response to adjuvant therapy or predicting disease progression in breast cancer is realized by (1) first obtaining a breast cancer test sample from a subject; (2) second obtaining clinicopathological data from said breast cancer test sample; (3) analyzing the obtained breast cancer test sample for presence or amount of (a) one or more molecular markers of hormone receptor status, one or more growth factor receptor markers, (b) one or more tumor suppression / apoptosis molecular markers; and (c) one or more additional molecular markers both proteomic and non-proteomic that are indicative of breast cancer disease processes; and then (4) correlating (a) the presence or amount of said molecular markers and, with (b) clinicopathological data from said tissue sample other than the molecular markers of breast cancer disease processes. A kit of (1) a panel of antibodies; (2) one or more gene amplification assays; (3) first reagents to assist said antibodies with binding to tumor samples; (4) second reagents to assist in determining gene amplification; permits, when applied to a breast cancer patient's tumor tissue sample, (A) permits observation, and determination, of a numerical level of expression of each individual antibody, and gene amplification; whereupon (B) a computer algorithm, residing on a computer can calculate a prediction of treatment outcome for a specific treatment for breast cancer, or future risk of breast cancer progression.

An integral laser imaging and treatment apparatus, and associated systems and methods that allow a physician (e.g., a surgeon) to perform laser surgical procedures on an eye structure or a body surface with an integral laser imaging and treatment apparatus disposed at a first (i.e. local) location from a control system disposed at a second (i.e. remote) location, e.g., a physician's office. In some embodiments, communication between the integral laser imaging and treatment apparatus and control system is achieved via the Internet®. Also, in some embodiments, the laser imaging and treatment apparatus includes a dynamic imaging system that verifies the identity of a patient, and is capable of being used for other important applications, such as tracking and analyzing trends in a disease process. Further, in some embodiments, the laser imaging and treatment apparatus determines the geographical location of the local laser generation unit of the system using GPS.

The present invention is directed towards compositions and methods for reducing or controlling inflammation and for treating inflammatory disease processes and other pathological conditions. The present invention relates to mixtures comprising at least one oligosaccharide of chitosan or a component thereof as novel pharmaceuticals, dietary supplements or cosmetic compositions containing such mixtures, and to the use of such mixtures for preparing a medicament or a dietary supplement for the suppression of hypersensitivity reaction and / or inflammation in human and animals.

The invention discloses nano-element traditional Chinese medicinal fabric antibacterial underwear for preventing and treating psoriasis, which belongs to the technical field of functional healthy fabric underwear production. Psoriasis is a skin disease which has high morbidity and stubborn disease process, is easy to relapse, is difficult to cure and does serious harm to the physical and psychological health of people. Far infrared heat effect takes effect in deep subcutaneous tissues through medical stone, tourmaline and a nano silver (Ag) antimicrobial agent, so the underwear expands blood vessels, quickens blood flow, increases cell activity and blood oxygen content, makes human bodies absorb more negative ions and trace elements, promotes body metabolism, enhances cellular immunity and humoral immunity of the human bodies, promotes the balance of elements in the human bodies, strengths the regeneration activity of cells and resists bacteria, cancers and inflammation. The underwear prevents and treats psoriasis when a user wears the underwear.

Contortrostatin, a homodimeric disintegrin, modulates the adhesion, motility, and invasiveness of integrin expressing tumor cells. When formulated as a pharmaceutically acceptable composition, the proteins can be used to treat patients by inhibiting or disrupting disease processes associated with an integrin binding to an αvβ3 or αvβ5 integrin.

The invention relates to the use of gene expression profiles, obtained in vitro from a patient sample, for the generation of criteria for the prediction of an individual course of disease in sepsis. The invention is further of use for determining the probability of survival in sepsis, the assessment of the course of disease in sepsis during treatment and for the classification of sepsis patients.